{"id":"NCT00675103","sponsor":"Savient Pharmaceuticals","briefTitle":"Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients","officialTitle":"Multicenter, Open-Label, 24 Week Regimen of 8 mg Pegloticase i.v. in Symptomatic Gout Subjects Who Participated in Previous Studies of Pegloticase i.v.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2009-01","completion":"2009-04","firstPosted":"2008-05-08","resultsPosted":"2011-06-28","lastUpdate":"2011-06-28"},"enrollment":7,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Gout Refractory to Conventional Therapy"],"interventions":[{"type":"DRUG","name":"pegloticase 8 mg i.v.","otherNames":[]}],"arms":[{"label":"pegloticase","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry.\n\nThis study is limited to four study centers in the US.","primaryOutcome":{"measure":"Adverse Event Profile","timeFrame":"6 months","effectByArm":[{"arm":"Pegloticase 8 mg Every 2 Wks","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Gout (flare)","Infusion-Related Reaction","Arthralgia","Fatigue","Oedema Peripheral"]}}